Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. ProMIS Neurosciences, Inc.
  6. News
  7. Summary
    PMN   CA74346M1095

PROMIS NEUROSCIENCES, INC.

(PMN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ProMIS Neurosciences : Presentations at 2021 Alzheimer's Association International Conference

08/02/2021 | 09:12am EDT
ProMIS Neurosciences Presentations at 2021 Alzheimer's Association International Conference

TORONTO, Ontario and CAMBRIDGE, Mass. - August 1, 2021 - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, gabve two presentations at the annual Alzheimer's Association International Conference (AAIC) held July 26-30, 2021 in Denver, USA and online.

ProMIS Chief Scientific Officer, Dr. Neil Cashman gave an oral presentation entitled: 'Selective targeting of intracellular misfolded, pathogenic TDP-43 with rationally designed intrabodies.'

Dr. Johanne Kaplan, ProMIS Chief Development Officer, presented the poster entitled: 'Conformational epitopes exposed on misfolded toxic forms of amyloid-beta, tau and alpha-synuclein directly contribute to their seeding activity.' The poster discusses conformational epitopes on misfolded proteins that represent unique targets for therapeutic antibodies.

Links to these presentation abstracts and poster below.

AAIC 2021 Cashman TDP43 abstract
AAIC 2021 Kaplan abstract
AAIC2021_ Cashman TDP43 presentation
Kaplan AAIC2021 Poster 55254

Disclaimer

ProMIS Neurosciences Inc. published this content on 02 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 August 2021 13:11:06 UTC.


ę Publicnow 2021
All news about PROMIS NEUROSCIENCES, INC.
09/16PROMIS NEUROSCIENCES : to Present at the Second Annual Undruggable Leaders Forum
AQ
09/15PROMIS NEUROSCIENCES : to Present at the Second Annual Undruggable Leaders Forum, Septembe..
AQ
09/15PROMIS NEUROSCIENCES : to Present at the Second Annual Undruggable Leaders Forum September..
PU
09/13PROMIS NEUROSCIENCES : to Participate in H.C. Wainwright & Co. 23rd Annual Investment Conf..
PU
09/01ProMIS Neurosciences Appoints "Accomplished" Biotechnology Executive, Josh Mandel-Brehm..
MT
09/01ProMIS Neurosciences, Inc. Appoints Josh Mandel-Brehm to Its Board of Directors
CI
09/01PROMIS NEUROSCIENCES : appoints accomplished biotechnology executive, Josh Mandel-Brehm, t..
PU
08/25PROMIS NEUROSCIENCES : Completes Public Unit Offering for Gross Proceeds of US$20.1 Millio..
MT
08/25ProMIS Neurosciences Closes Upsized US$20,125,000 Public Offering
GL
08/25ProMIS Neurosciences, Inc. announced a financing transaction
CI
More news
Financials
Sales 2020 0,00 M 0,00 M 0,00 M
Net income 2020 -5,66 M -4,47 M -4,47 M
Net cash 2020 1,07 M 0,85 M 0,85 M
P/E ratio 2020 -3,96x
Yield 2020 -
Capitalization 79,9 M 62,9 M 63,1 M
EV / Sales 2019 37 534x
EV / Sales 2020 15 614x
Nbr of Employees -
Free-Float 95,1%
Chart PROMIS NEUROSCIENCES, INC.
Duration : Period :
ProMIS Neurosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROMIS NEUROSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Managers and Directors
Elliot Goldstein President, Chief Executive Officer & Director
Daniel E. Geffken Chief Financial Officer
Eugene Williams Executive Chairman
Neil R. Cashman Director & Chief Scientific Officer
William W. Wyman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PROMIS NEUROSCIENCES, INC.85.00%63
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
REGENERON PHARMACEUTICALS32.25%66 425
WUXI APPTEC CO., LTD.34.39%59 817
VERTEX PHARMACEUTICALS-22.31%47 634